- Home
- BREA vs BCTX Comparison
BREA vs BCTX Comparison
Compare BREA & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- BCTX
- Stock Information
- Founded
- BREA 2022
- BCTX 2014
- Country
- BREA Ireland
- BCTX Canada
- Employees
- BREA N/A
- BCTX N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- BCTX Health Care
- Exchange
- BREA Nasdaq
- BCTX Nasdaq
- Market Cap
- BREA 14.8M
- BCTX 14.2M
- IPO Year
- BREA 2023
- BCTX N/A
- Fundamental
- Price
- BREA $7.64
- BCTX $8.78
- Analyst Decision
- BREA
- BCTX Strong Buy
- Analyst Count
- BREA 0
- BCTX 1
- Target Price
- BREA N/A
- BCTX $40.00
- AVG Volume (30 Days)
- BREA 216.2K
- BCTX 79.1K
- Earning Date
- BREA 01-01-0001
- BCTX 10-28-2025
- Dividend Yield
- BREA N/A
- BCTX N/A
- EPS Growth
- BREA N/A
- BCTX N/A
- EPS
- BREA N/A
- BCTX N/A
- Revenue
- BREA $2,988,009.00
- BCTX N/A
- Revenue This Year
- BREA N/A
- BCTX N/A
- Revenue Next Year
- BREA N/A
- BCTX N/A
- P/E Ratio
- BREA N/A
- BCTX N/A
- Revenue Growth
- BREA 151.51
- BCTX N/A
- 52 Week Low
- BREA $5.00
- BCTX $6.00
- 52 Week High
- BREA $19.50
- BCTX $214.50
- Technical
- Relative Strength Index (RSI)
- BREA 63.62
- BCTX 53.46
- Support Level
- BREA $5.87
- BCTX $7.66
- Resistance Level
- BREA $14.84
- BCTX $8.20
- Average True Range (ATR)
- BREA 0.96
- BCTX 0.41
- MACD
- BREA 0.19
- BCTX -0.10
- Stochastic Oscillator
- BREA 21.14
- BCTX 98.12
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.